The Bull Rankings scorecard — our quality-growth score is 63.2 / 100, built from three pillars scored 0–100: Quality 74, Growth 67, Value 51 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 4% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Avery Dennison is a compounder disguised as a stodgy label maker. The numbers in the quarter ended 2026-06-30 say as much: revenue grew 5.8% year over year while the company printed a 30.3% return on equity and cranked out $1.1 billion in free cash flow over the trailing twelve months. Our model’s quality-growth score of 63.2/100 is anchored by its strongest pillar—Quality at 74—because the business turns capital into cash with unusual efficiency. The weakest pillar, Value at 51, tells the rest of the story: the stock sits at 19.5 times trailing earnings, yet the reverse-DCF implies roughly -4% annual free-cash-flow growth (in year one, recovering toward 3% a year by year ten). The bull case is simple: a high-quality franchise with durable returns and a management team that rewards shareholders with buybacks and dividend increases. The bear case is equally simple: the multiple leaves little cushion if the business stumbles.
What the business actually is
Avery Dennison sells pressure-sensitive labels, performance tapes, and graphics films under brands like Fasson, JAC, and Avery Dennison. The labels—made from paper, plastic films, and metal foils—wrap consumer goods, medical devices, and industrial parts. The tapes include mechanical fasteners that replace screws or welds in everything from smartphones to cars. The graphics business coats films for digital printing, commercial signage, and reflective safety gear. Each segment is sticky because customers design around Avery’s materials; switching costs aren’t just dollars, they’re engineering hours.
Why it can (or can't) keep compounding
The moat is the flywheel between R&D and scale. Avery’s labels and tapes command premium pricing because the company co-develops adhesives and substrates with customers, locking in specifications that competitors can’t replicate overnight. That engineering advantage shows up in the 30.3% return on equity in the quarter ended 2026-06-30—and a 7.6% profit margin that has held steady even as raw-material costs bounced around. Our model’s signal that management is buying back stock and raising the dividend fits the pattern: capital discipline meets recurring demand. The risk is that a step-change in substrate technology—say, a biodegradable film that undercuts Avery’s legacy plastics—erodes pricing power. Until then, the machine keeps spinning.
The valuation question
The stock at $178.34 is trading at 19.5 times trailing earnings, which isn’t cheap, but the real tell is the reverse-DCF. Our model reads that today’s price embeds roughly -4% annual free-cash-flow growth (in year one, recovering toward 3% a year by year ten). That’s a steep hurdle for a business that just grew revenue 5.8% and generated $1.1 billion in free cash flow over the trailing twelve months. The implied growth is far below the company’s historical cadence, suggesting the market has already discounted a slowdown. Put differently, the price leaves room for upside if free cash flow surprises.
The bear case
The weakest pillar—Value at 51—is the clearest warning. The debt-to-equity ratio of 1.59 is manageable but not trivial, and the 7.6% profit margin, while resilient, leaves little room for error if input costs rise or pricing power slips. The reverse-DCF’s implied -4% free-cash-flow growth is the number that should keep skeptics up at night: it assumes free cash flow shrinks next year and only recovers toward 3% a year by year ten, while investors wait for the multiple to rerate. Until revenue growth accelerates or margins expand, the stock is a bet on stability, not acceleration.
What would change our mind
Two metrics would flip the thesis. First, if the return on equity dips below 28%, the compounding story weakens. Second, if free-cash-flow growth turns positive and sustains above 2% annually, the reverse-DCF’s implied -4% read would look overly pessimistic. Either shift would need to show up in the quarterly filings before the market rerates the stock.